Towards effective radiation protection based on improved scientific evidence and social considerations – focus on Radon and NORM. RadoNorm is designed to initiate and perform research and technical development in support of EU Member States, Associated Countries and the European Commission in their efforts to implement the European radiation protection Basic Safety Standards. The proposed
Project ROUTES (Waste Management Routes in Europe from Cradle-to-Grave) it is a strategic project of the EJP-EURAD H2020, involving 36 European Institutions aiming at sharing knowledge and experience between Member States (small and large radwaste inventories) about scientific and technical issues identified as common priorities, including pre-disposal (characterization, treatment, storage and conditioning) and disposal, shared
PRISMAP is a European project aiming to supply in a sustained manner innovative medical radionuclides, to promote a paradigm shift in the research of new radiopharmaceuticals for the diagnostic and therapy of cancer towards the development of theranostics and rise of personalized medicine. Coordinator at IST: António Paulo – apaulo@ctn.tecnico.ulisboa.pt https://www.prismap.eu/
The PANORAMA project aims to consider the whole REE environmental behaviour. (Geo)chemists, (hydro)geologists and (eco)toxicologists, gathered within a consortium of 14 academic partner and 4 non-academic partners aims to consider the whole REE environmental behavior. PhD students (15) are training to develop skillset in basic research and cross-cutting skills, all within a high-level European intersectoral
SECURE project is focused on the characterization of possible side-effects induced in cellulose-based materials by ionizing radiation, mainly high energetic proton beams, gamma, X-ray and electrons beams. In this project participate: C2TN, Department of Conservation and Restoration from NOVA University and Neon Art Conservation. Coordinator at IST: Victoria Corregidor – victoria.corregidor@ctn.tecnico.ulisboa.pt
Lutetium-177 (Lu-177) is currently the most important therapeutic radionuclide and it will continue to be a key role player in the nuclear medicine field, as its half-life of 6.65 days allows logistic of production and supply of radioisotope and finished product. Currently there are over 70 radiopharmaceuticals for therapy in clinical trials and about 40%